1. Among patients with previously untreated programmed death-ligand 1 positive, triple-negative breast cancer, first-line sacituzumab govitecan plus pembrolizumab significantly prolonged ...
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
Click to read this study in The Lancet Oncology.
1. In the pembrolizumab arm, distant metastasis-free survival was significantly improved and the risk of recurrence remained lower than the ...
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage melanoma There was no significant difference in ...
1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in PD-L1 unselected non-small-cell lung cancer patients who underwent ...
